GSA Capital Partners LLP Grows Position in Codexis, Inc. (NASDAQ:CDXS)

GSA Capital Partners LLP increased its position in Codexis, Inc. (NASDAQ:CDXS) by 83.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,629 shares of the biotechnology company’s stock after purchasing an additional 45,337 shares during the quarter. GSA Capital Partners LLP owned approximately 0.12% of Codexis worth $307,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC purchased a new position in shares of Codexis in the 2nd quarter valued at approximately $54,000. Marshall Wace LLP purchased a new position in Codexis during the second quarter valued at $89,000. State Board of Administration of Florida Retirement System raised its stake in Codexis by 57.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 28,500 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 10,395 shares during the last quarter. SG Americas Securities LLC raised its stake in Codexis by 72.6% during the second quarter. SG Americas Securities LLC now owns 36,677 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 15,425 shares during the last quarter. Finally, Algert Global LLC raised its stake in Codexis by 17.1% during the second quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 6,069 shares during the last quarter. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Stock Up 6.5 %

Codexis stock opened at $4.61 on Friday. The firm has a market cap of $375.16 million, a price-to-earnings ratio of -5.30 and a beta of 2.07. The stock has a fifty day simple moving average of $3.42 and a two-hundred day simple moving average of $3.26. Codexis, Inc. has a 12 month low of $1.85 and a 12 month high of $4.91. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS) last posted its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The business had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. During the same period in the previous year, the business posted ($0.26) EPS. Equities analysts predict that Codexis, Inc. will post -0.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Opaleye Management Inc. acquired 45,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was bought at an average price of $2.94 per share, with a total value of $132,300.00. Following the completion of the acquisition, the insider now directly owns 8,435,000 shares of the company’s stock, valued at approximately $24,798,900. The trade was a 0.54 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders acquired 1,166,000 shares of company stock valued at $3,514,910. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CDXS shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price objective on shares of Codexis in a research note on Friday. Benchmark reiterated a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.